CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics to
treat serious and rare diseases, today announced that it has issued
810,810 shares of common stock at the public offering price of $37.00
per share, pursuant to the full exercise of the underwriters'
over-allotment option in connection with the Company's previously
announced public offering of common stock. The aggregate net proceeds to
the Company of the public offering, including the full exercise of the
over-allotment option and after deducting underwriting discounts and
commissions and other estimated offering expenses, were
approximately $215.8 million.
J.P. Morgan Securities LLC, Citigroup and Leerink Partners LLC acted as
joint book-running managers for the offering.
The shares were offered by Acceleron pursuant to an effective shelf
registration statement on Form S-3 that was previously filed with the
Securities and Exchange Commission (the "SEC"). A preliminary prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC on September 19, 2017. The final prospectus
supplement relating to the offering was filed with the SEC on September
21, 2017. Copies of the final prospectus supplement and the accompanying
prospectus can be obtained at the SEC's website http://www.sec.gov
or from J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone:
1-866-803-9204 or email: firstname.lastname@example.org;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146; and
Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA, 02110, or by e-mail at Syndicate@Leerink.com,
or by phone at 800-808-7525, ext. 6132.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in which
an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of such jurisdiction.
Acceleron is a leading biopharmaceutical company in the discovery and
development of TGF-beta therapeutics to treat serious and rare diseases.
Its pioneering research and protein engineering platform engages the
target-rich TGF-beta superfamily and its remarkable ability to regulate
cellular growth and repair.
Under a global partnership with Celgene, Acceleron is in Phase 3
development with luspatercept, a potential first-in-class chronic anemia
therapy for the treatment of rare blood diseases. The Company is also
advancing a neuromuscular franchise with two distinct Myostatin+ agents,
ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of
sotatercept planned in pulmonary arterial hypertension. Acceleron has
ongoing preclinical research efforts targeting additional indications in
these three disease areas where there is significant unmet medical need.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties that could
cause actual results to differ materially from those in the
forward-looking statements. These risks and uncertainties include, but
are not limited to, risks and uncertainties associated with the
consummation of the proposed offering and general economic conditions
and other risks identified from time to time in the reports we file with
the SEC, including our Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov.
We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. The
forward-looking statements in this press release speak only as of the
date of this document, and we undertake no obligation to update or
revise any of the statements. Our business is subject to substantial
risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to
these risks and uncertainties.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005360/en/
Todd James, 617-649-9393
President, Investor Relations and Corporate Communications
Brad Miles, 917-570-7340
Source: Acceleron Pharma Inc.
News Provided by Acquire Media